Drug and Alcohol Dependence, Год журнала: 2021, Номер 229, С. 109159 - 109159
Опубликована: Окт. 29, 2021
Язык: Английский
Diabetes Care, Год журнала: 2023, Номер 47(Supplement_1), С. S77 - S110
Опубликована: Дек. 11, 2023
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide components diabetes care, general treatment goals guidelines, tools evaluate quality care. Members ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating Standards annually, or more frequently as warranted. For a detailed description standards, statements, reports, well evidence-grading system full list Committee members, please refer Introduction Methodology. Readers who wish comment on invited do so at professional.diabetes.org/SOC.
Язык: Английский
Процитировано
150
The Lancet Psychiatry, Год журнала: 2022, Номер 9(9), С. 736 - 750
Опубликована: Июль 25, 2022
Язык: Английский
Процитировано
133
The Lancet Regional Health - Europe, Год журнала: 2021, Номер 10, С. 100227 - 100227
Опубликована: Сен. 24, 2021
Cannabis is one of the most widely used substances worldwide. Heavy use associated with an increased risk cannabis disorders, psychotic acute cognitive impairment, traffic injuries, respiratory problems, worse pregnancy outcomes, and there are indications for genotoxic epigenotoxic adverse effects. International regulation medical non-medical changing rapidly substantially, highlighting importance robust public health monitoring. This study aimed to describe trends key indicators in European Union (27 member states + UK, Norway Turkey) period 2010 2019, their implications, identify steps required improve current practice monitoring harm Europe.Data on four (prevalence use, prevalence disorder [CUD], treatment rates, potency products) Europe were extracted from United Nations Office Drugs Crime, Monitoring Centre Drug Addiction Global Burden Disease study. For CUD, first last available estimate each country compared. rates potency, linear regression models conducted.Between past-month by 27% adults (from 3·1 3·9%), pronounced relative increases observed among 35-64 year-olds. In 13 out 26 countries, over 20% all users reported high-risk patterns. The rate entry problems per 100,000 27·0 (95% CI: 17·2 36·8) 35·1 23·6 46·7) has mostly plateaued since 2015. Modest found herbal 6·9% 10·6% THC) while median THC values tripled resin 7·6% 24·1% THC).In past decade, levels have major concerns about impact use. Continued efforts data quality reporting, including cannabis-attributable harm, will be necessary evaluate international changes regulation.This received no specific funding.
Язык: Английский
Процитировано
129
BMC Medicine, Год журнала: 2022, Номер 20(1)
Опубликована: Авг. 19, 2022
Medical cannabinoids differ in their pharmacology and may have different treatment effects. We aimed to conduct a pharmacology-based systematic review (SR) meta-analyses of medical for efficacy, retention adverse events.We systematically reviewed (registered at PROSPERO: CRD42021229932) eight databases randomized controlled trials (RCTs) dronabinol, nabilone, cannabidiol nabiximols chronic pain, spasticity, nausea /vomiting, appetite, ALS, irritable bowel syndrome, MS, Chorea Huntington, epilepsy, dystonia, Parkinsonism, glaucoma, ADHD, anorexia nervosa, anxiety, dementia, depression, schizophrenia, PTSD, sleeping disorders, SUD Tourette. Main outcomes measures included patient-relevant/disease-specific outcomes, events. Data were calculated as standardized mean difference (SMD) ORs with confidence intervals (CI) via random Evidence quality was assessed by the Cochrane Risk Bias GRADE tools.In total, 152 RCTs (12,123 participants) analysed according type cannabinoid, outcome comparator used, resulting 84 comparisons. Significant therapeutic effects show large variability grade evidence that depends on cannabinoid. CBD has significant effect epilepsy (SMD - 0.5[CI 0.62, 0.38] high grade) Parkinsonism (- 0.41[CI 0.75, 0.08] moderate grade). There is dronabinol pain 0.31[CI 0.46, 0.15]), appetite 0.51[CI 0.87, 0.15]) Tourette 1.01[CI 1.58, 0.44]) 0.25[- 0.37, 0.14]), spasticity 0.36[CI 0.54, 0.19]), sleep 0.24[CI 0.35, 0.14]) SUDs 0.48[CI 0.92, 0.04]). All other either low, very or even no evidence. Cannabinoids produce events, there low this conclusion depending cannabinoid.Cannabinoids are effective therapeutics several indications if specific pharmacological properties considered. suggest future studies cannabinoid field should be based upon pharmacology.
Язык: Английский
Процитировано
110
Опубликована: Июнь 30, 2023
SEM RESUMO
Процитировано
78
Diabetes Care, Год журнала: 2024, Номер 48(Supplement_1), С. S86 - S127
Опубликована: Дек. 9, 2024
The American Diabetes Association (ADA) "Standards of Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide components diabetes care, general treatment goals guidelines, tools evaluate quality care. Members ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating Standards annually, or more frequently as warranted. For a detailed description standards, statements, reports, well evidence-grading system full list Committee members, please refer Introduction Methodology. Readers who wish comment on invited do so at professional.diabetes.org/SOC.
Язык: Английский
Процитировано
28
Addiction, Год журнала: 2021, Номер 117(6), С. 1510 - 1517
Опубликована: Сен. 30, 2021
Abstract Background The lack of an agreed international minimum approach to measuring cannabis use hinders the integration multidisciplinary evidence on psychosocial, neurocognitive, clinical and public health consequences use. Methods A group 25 expert researchers convened discuss a framework for standards measure globally in diverse settings. Results expert‐based consensus upon three‐layered hierarchical framework. Each layer—universal measures, detailed self‐report biological measures—reflected different research priorities standards, costs ease implementation. Additional work is needed develop valid precise assessments. Conclusions Consistent proposed across research, health, practice medical settings would facilitate harmonisation consumption, related harms approaches their mitigation.
Язык: Английский
Процитировано
71
International Journal of Drug Policy, Год журнала: 2022, Номер 105, С. 103716 - 103716
Опубликована: Май 23, 2022
Язык: Английский
Процитировано
69
Neuropsychopharmacology, Год журнала: 2022, Номер 48(6), С. 869 - 876
Опубликована: Ноя. 16, 2022
As countries adopt more permissive cannabis policies, it is increasingly important to identify strategies that can reduce the harmful effects of use. This study aimed determine if increasing CBD content its effects. Forty-six healthy, infrequent users participated in a double-blind, within-subject, randomised trial preparations varying content. There was an initial baseline visit followed by four drug administration visits, which participants inhaled vaporised containing 10 mg THC and either 0 (0:1 CBD:THC), (1:1), 20 (2:1), or 30 (3:1) CBD, randomised, counter-balanced order. The primary outcome change delayed verbal recall on Hopkins Verbal Learning Task. Secondary outcomes included severity psychotic symptoms (e.g., Positive Negative Syndrome Scale [PANSS] positive subscale), plus further cognitive, subjective, pleasurable, pharmacological physiological Serial plasma concentrations were measured. (0:1) associated with impaired (t(45) = 3.399, d 0.50, p 0.001) induced PANSS -4.709, 0.69, 2.41 × 10-5). These not significantly modulated any dose CBD. Furthermore, there no evidence modulating other psychotic, measures. dose-response relationship between concentration, effect concentrations. At CBD:THC ratios most common medicinal recreational products, we found protects against acute adverse cannabis. should be considered health policy safety decisions about
Язык: Английский
Процитировано
63
JAMA Pediatrics, Год журнала: 2021, Номер 176(1), С. 42 - 42
Опубликована: Окт. 25, 2021
Vaping products were initially designed to deliver nicotine as a tobacco cigarette substitute (eg, electronic cigarettes) but are now frequently used psychoactive substances, such cannabis and its derivatives. Large, nationally representative surveys, Monitoring the Future, found that approximately 1 in 3 grade-12 students vaped 2018 alone.To summarize findings of epidemiological studies reported global prevalence vaping adolescents by survey year school grades.PubMed, PsycINFO, Scopus, Web Science searched systematically on August 19, 2020, for published globally between January 1, 2003, 2020.Publications general population included.Study characteristics estimates extracted from each article. Random-effects meta-analysis based DerSimonian Laird method meta-regression performed lifetime, 12-month, 30-day estimates. Meta-regression was also conducted using grades moderators.Prevalence vaping.Seventeen met eligibility criteria (n = 198 845 adolescents). Although no restrictions imposed study location, all 17 US Canada. Across grades, pooled increased lifetime use (6.1% 2013-2016 13.6% 2019-2020), past 12 months (7.2% 2017-2018 13.2% 30 days (1.6% 8.4% 2019-2020). Heterogeneity across large. The limited evidence similar designs suggested adolescents' preference other than dried herbs, which usually contain higher Δ9-tetrahydrocannabinol levels, may have shifted over time.The this suggest has among Canada more effective preventive response measures required.PROSPERO Identifier: CRD42020219644.
Язык: Английский
Процитировано
59